The Inflammatory and Hemostatic Cardiovascular Risk Markers During Acute Hyperglycemic Crisis in Type 1 and Type 2 Diabetes.
acute hyperglycemic crisis
cardiovascular risk markers
haemostatic markers
inflammatory markers
Journal
Journal of medical biochemistry
ISSN: 1452-8258
Titre abrégé: J Med Biochem
Pays: Serbia
ID NLM: 101315490
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
03
04
2018
accepted:
05
06
2018
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
15
3
2019
Statut:
epublish
Résumé
We analyzed cardiovascular inflammatory (C-reactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). In that context, we included group A: N = 20 obese, B: N=20 lean patients with DKA; C: N = l0 obese, D: N=10 lean patients with HHS; E: N = 15 obese, F: N=15 lean controls. CRP IL-6, homocysteine were determined by ELISA. Our results showed that CRP IL-6, and homocysteine levels decreased in all groups: (A: p<0.001; B: p<0.001, C: p<0.05; D: p<0.001 mg/L), (A: p<0.001 B: p<0.001, C: p<0.001, D: p<0.01 pg/mL), (A: p<0.001, B: p <0.001; C: p<0.05, D: p=0.001 μmol/L), respectively, at resolving AHC. However, CRP persisted higher (p<0.001, p<0.01), IL-6 lower (p<0.05, p<0.001), while homocysteine levels turned out to be similar to controls. AHC is associated with increased inflammatory and hemostatic cardiovascular risk markers. Also, insulin therapy in AHC has had more pronounced favorable effect on IL-6 and homocystein than on CRP. Analizirali smo kardiovaskularne inflamatorne (C-reaktivni protein (CRP), interleukin 6 (IL-6)) i (homocistein) hemotatske markere rizika u negojaznih i gojaznih pacijenata pri prijemu i razrešenju akutne hiperglikemijske krize (AHK), uključujući dijabetesnu ketoacidozu (DKA) i hiperosmolarno hiperglikemijsko stanje (HHS). U tom kontekstu uključili smo grupu A: N = 20 gojaznih, B: N = 20 negojaznih bolesnika sa DKA; C: N = 10 gojaznih, D: N = 10 negojaznih bolesnika sa HHS; E: N = 15 gojaznih, F: N = 15 negojaznih kontrola. Nivo CRP IL-6 i homocistein određeni su ELISA metodom. Naši rezultati su pokazali niže nivoe CRP IL-6 i homocisteina nakon rešavanja AHK u poređenju sa prijemom u svim grupama: (A: p<0,001; B: p<0,001, C: p<0,05; D: p<0,001 mg/L), (A: p<0,001 B: p <0,001; C: p<0,05, D: p=0,001 mmol/L), (A: p<0,00l, B: p<0,001, C: p<0,001, D: p<0,01 pg/mL) nakon rešavanja AHK. Međutim, nivo CRP je ostao viši (p<0,001, p <0,01), IL-6 niži (p<0,05, p<0,001), dok je nivo homocisteina sličan u poređenju sa kontrolama. AHK su povezane sa povišenim nivoom inflamatornih i hemostatičnih kardiovaskularnih markera rizika. Takođe, terapija insulinom u AHK ima značajno povoljniji efekat na nivo IL-6 i homocisteina, nego na nivo CRP.
Sections du résumé
BACKGROUND
BACKGROUND
We analyzed cardiovascular inflammatory (C-reactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS).
METHODS
METHODS
In that context, we included group A: N = 20 obese, B: N=20 lean patients with DKA; C: N = l0 obese, D: N=10 lean patients with HHS; E: N = 15 obese, F: N=15 lean controls. CRP IL-6, homocysteine were determined by ELISA.
RESULTS
RESULTS
Our results showed that CRP IL-6, and homocysteine levels decreased in all groups: (A: p<0.001; B: p<0.001, C: p<0.05; D: p<0.001 mg/L), (A: p<0.001 B: p<0.001, C: p<0.001, D: p<0.01 pg/mL), (A: p<0.001, B: p <0.001; C: p<0.05, D: p=0.001 μmol/L), respectively, at resolving AHC. However, CRP persisted higher (p<0.001, p<0.01), IL-6 lower (p<0.05, p<0.001), while homocysteine levels turned out to be similar to controls.
CONCLUSIONS
CONCLUSIONS
AHC is associated with increased inflammatory and hemostatic cardiovascular risk markers. Also, insulin therapy in AHC has had more pronounced favorable effect on IL-6 and homocystein than on CRP.
UVOD
UNASSIGNED
Analizirali smo kardiovaskularne inflamatorne (C-reaktivni protein (CRP), interleukin 6 (IL-6)) i (homocistein) hemotatske markere rizika u negojaznih i gojaznih pacijenata pri prijemu i razrešenju akutne hiperglikemijske krize (AHK), uključujući dijabetesnu ketoacidozu (DKA) i hiperosmolarno hiperglikemijsko stanje (HHS).
METODE
METHODS
U tom kontekstu uključili smo grupu A: N = 20 gojaznih, B: N = 20 negojaznih bolesnika sa DKA; C: N = 10 gojaznih, D: N = 10 negojaznih bolesnika sa HHS; E: N = 15 gojaznih, F: N = 15 negojaznih kontrola. Nivo CRP IL-6 i homocistein određeni su ELISA metodom.
REZULTATI
UNASSIGNED
Naši rezultati su pokazali niže nivoe CRP IL-6 i homocisteina nakon rešavanja AHK u poređenju sa prijemom u svim grupama: (A: p<0,001; B: p<0,001, C: p<0,05; D: p<0,001 mg/L), (A: p<0,001 B: p <0,001; C: p<0,05, D: p=0,001 mmol/L), (A: p<0,00l, B: p<0,001, C: p<0,001, D: p<0,01 pg/mL) nakon rešavanja AHK. Međutim, nivo CRP je ostao viši (p<0,001, p <0,01), IL-6 niži (p<0,05, p<0,001), dok je nivo homocisteina sličan u poređenju sa kontrolama.
ZAKLJUČAK
UNASSIGNED
AHK su povezane sa povišenim nivoom inflamatornih i hemostatičnih kardiovaskularnih markera rizika. Takođe, terapija insulinom u AHK ima značajno povoljniji efekat na nivo IL-6 i homocisteina, nego na nivo CRP.
Autres résumés
Type: Publisher
(srp)
Analizirali smo kardiovaskularne inflamatorne (C-reaktivni protein (CRP), interleukin 6 (IL-6)) i (homocistein) hemotatske markere rizika u negojaznih i gojaznih pacijenata pri prijemu i razrešenju akutne hiperglikemijske krize (AHK), uključujući dijabetesnu ketoacidozu (DKA) i hiperosmolarno hiperglikemijsko stanje (HHS).
Identifiants
pubmed: 30867640
doi: 10.2478/jomb-2018-0024
pii: jomb-2018-0024
pmc: PMC6410996
doi:
Types de publication
Journal Article
Langues
eng
Pagination
126-133Déclaration de conflit d'intérêts
Conflict of interest Conflict of interest statement: The authors stated that they have no conflicts of interest regarding the publication of this article.
Références
Am J Clin Nutr. 2000 Jul;72(1):22-9
pubmed: 10871556
Endocrinology. 2000 Jul;141(7):2582-8
pubmed: 10875261
Life Sci. 2000 Jun 8;67(3):291-300
pubmed: 10983873
Diabetes Care. 2000 Dec;23(12):1816-22
pubmed: 11128359
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099
Diabetes Care. 2001 Aug;24(8):1403-10
pubmed: 11473077
Diabetologia. 2001 Aug;44(8):1011-4
pubmed: 11484078
Am J Epidemiol. 2002 Jan 1;155(1):65-71
pubmed: 11772786
J Clin Endocrinol Metab. 2002 Mar;87(3):1419-22
pubmed: 11889219
Drugs. 2002;62(4):605-16
pubmed: 11893229
Circulation. 2002 Oct 15;106(16):2067-72
pubmed: 12379575
J Clin Endocrinol Metab. 2003 Mar;88(3):1082-8
pubmed: 12629088
Diabetes Care. 2003 May;26(5):1535-9
pubmed: 12716818
Clin Immunol. 2003 Sep;108(3):175-81
pubmed: 14499240
Ann Clin Lab Sci. 2003 Fall;33(4):435-42
pubmed: 14584758
Biochem Biophys Res Commun. 2004 Mar 5;315(2):404-7
pubmed: 14766222
Diabetes. 2004 Aug;53(8):2079-86
pubmed: 15277389
Int J Obes Relat Metab Disord. 2004 Sep;28 Suppl 2:S3-7
pubmed: 15306831
Diabetes. 2005 Jan;54(1):85-91
pubmed: 15616014
Eur Heart J. 2005 Feb;26(4):328-31
pubmed: 15618047
Diabetologia. 2005 Jun;48(6):1038-50
pubmed: 15864529
Nutr Metab Cardiovasc Dis. 2005 Apr;15(2):118-24
pubmed: 15871860
Biochem Biophys Res Commun. 2005 Sep 23;335(2):491-5
pubmed: 16084832
J Am Soc Nephrol. 2006 Mar;17(3):863-70
pubmed: 16467451
Eur J Endocrinol. 2006 Dec;155(6):887-93
pubmed: 17132759
Diabetes Care. 2007 Apr;30(4):854-60
pubmed: 17392546
J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S14-20
pubmed: 19179212
Diabetes Care. 2009 Jul;32(7):1335-43
pubmed: 19564476
N Am J Med Sci. 2012 Apr;4(4):180-4
pubmed: 22536561
BMC Genomics. 2013 Dec 10;14:867
pubmed: 24320691
Cardiovasc J Afr. 2014 May-Jun;25(3):137-41
pubmed: 25000444
J Diabetes Complications. 2014 Sep-Oct;28(5):662-6
pubmed: 25044235
PLoS One. 2015 Aug 27;10(8):e0136840
pubmed: 26313920
J Med Biochem. 2017 Jul 14;36(3):211-215
pubmed: 30564057
J Med Biochem. 2018 Jul 01;37(3):373-378
pubmed: 30598635
Metabolism. 1998 Jun;47(6):686-9
pubmed: 9627367
Circulation. 1998 Jul 21;98(3):204-10
pubmed: 9697819